<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immunome Inc — News on 6ix</title>
<link>https://6ix.com/company/immunome-inc</link>
<description>Latest news and press releases for Immunome Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immunome-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835838178dffbe2df0fcb94.webp</url>
<title>Immunome Inc</title>
<link>https://6ix.com/company/immunome-inc</link>
</image>
<item>
<title>Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announces-submission-of-new-drug-application-to-us-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announces-submission-of-new-drug-application-to-us-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors</guid>
<pubDate>Wed, 29 Apr 2026 11:30:00 GMT</pubDate>
<description>BOTHELL, Wash., April 29, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.</description>
</item>
<item>
<title>Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announces-oral-presentation-of-phase-3-ringside-data-at-2026-asco-annual-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announces-oral-presentation-of-phase-3-ringside-data-at-2026-asco-annual-meeting-1</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and</description>
</item>
<item>
<title>Immunome Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 03 Mar 2026 21:02:00 GMT</pubDate>
<description>BOTHELL, Wash., March 03, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-02-05</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-02-05</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and</description>
</item>
<item>
<title>Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announces-pricing-public-offering-common-stock-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announces-pricing-public-offering-common-stock-2025-12-17</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class</description>
</item>
<item>
<title>Immunome Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announces-proposed-public-offering-common-stock-2025-12-15</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announces-proposed-public-offering-common-stock-2025-12-15</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class</description>
</item>
<item>
<title>Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announces-positive-topline-results-phase-3-ringside-trial-varegacestat</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announces-positive-topline-results-phase-3-ringside-trial-varegacestat</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16,</description>
</item>
<item>
<title>Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-announce-topline-results-phase-3-ringside-trial-varegacestat-patients</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-announce-topline-results-phase-3-ringside-trial-varegacestat-patients</guid>
<pubDate>Sun, 14 Dec 2025 05:00:00 GMT</pubDate>
<description>Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company</description>
</item>
<item>
<title>Immunome to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-upcoming-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-upcoming-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-2nd-annual-guggenheim-healthcare-innovation-conference-2025-10-31</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-2nd-annual-guggenheim-healthcare-innovation-conference-2025-10-31</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-presents-preclinical-data-showing-proprietary-top1i-adc-payload-hc74</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-presents-preclinical-data-showing-proprietary-top1i-adc-payload-hc74</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-hc-wainwright-27th-annual-global-investment-conference-2025-09-03</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-hc-wainwright-27th-annual-global-investment-conference-2025-09-03</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-second-quarter-2025-200500519</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-second-quarter-2025-200500519</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>BOTHELL, Wash., August 06, 2025--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update.</description>
</item>
<item>
<title>Immunome to Present at Upcoming Investor Conferences </title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-upcoming-investor-conferences-2025-05-22</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-upcoming-investor-conferences-2025-05-22</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-first-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-first-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-present-24th-annual-needham-virtual-healthcare-conference-2025-04-04</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-present-24th-annual-needham-virtual-healthcare-conference-2025-04-04</guid>
<pubDate>Fri, 04 Apr 2025 04:00:00 GMT</pubDate>
<description>BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted</description>
</item>
<item>
<title>Immunome Reports Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/immunome-inc/news/immunome-reports-full-year-2024-financial-results-and-provides-business-update-2025</link>
<guid isPermaLink="true">https://6ix.com/company/immunome-inc/news/immunome-reports-full-year-2024-financial-results-and-provides-business-update-2025</guid>
<pubDate>Wed, 19 Mar 2025 04:00:00 GMT</pubDate>
<description>Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025. First patient dosed in Phase 1</description>
</item>
</channel>
</rss>